Insights on the Insulin Global Market to 2028

Company logo

Company logo

Global insulin market

Global insulin market

Global insulin market

Dublin, Nov. 21, 2022 (GLOBE NEWSWIRE) — The “Insulin Market Forecast to 2028 – Impact of COVID-19 and Global Analysis by Type and Geography” report has been added. at ResearchAndMarkets.com offer

The insulin market is projected to grow from USD 54,611.42 billion in 2021 to USD 111,213.73 billion by 2028. It is projected to grow at a CAGR of 10.8% from 2022 to 2028.

Increasing incidence of diabetes and rapid technological development in insulin delivery devices are key players expected to boost the insulin market in the coming years. Furthermore, diabetic pancreas regeneration with advanced transplants is likely to emerge as a significant future trend in the insulin market from 2022 to 2028. However, risks associated with insulin delivery devices hinder the overall growth of the market.

In diabetic people, the pancreas does not produce enough insulin, or the body does not respond normally to insulin, causing blood glucose levels to rise. Insulin is a hormone that helps lower blood sugar levels. Insulin therapy is often an essential part of diabetes treatment. It is made by the beta cells of the pancreas and is released into the blood when glucose levels rise, for example after eating.

Insulin helps glucose enter the body’s cells, where it can be stored for energy or future use. The different types of insulin available vary in how quickly and for how long they can control blood sugar. Insulin does not come in pill form because it would be broken down by the digestive system before it can work. Insulin therapy is exhausting; however, it is an effective way to lower blood sugar levels.

Products with advanced insulin technology with more benefits are essential for the treatment of diabetes. Advances in the treatment of diabetes have increased in recent years. As the prevalence of diabetes is increasing worldwide, the demand for advanced products is also increasing. The insulin market is expected to grow due to increased strategic efforts by industry players. Market players actively support their research and public and private academic institutes to increase their research activities.

Some of the recent developments associated with rapid technological advancements in the insulin market are mentioned below:
In May 2022, Eli Lilly and Company received US FDA approval for its once-weekly Mounjar (tirzepatide) glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 glucagon-like peptide-1 (GLP-1) receptor agonist. Adults with type 2 diabetes. The injection is decided to be available in 6 doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) as a pre-attached self-injection pen with a hidden needle.

Main topics covered:

1. Introduction

2. Insulin market – Key takeaways

3. Research Methodology

4. Insulin Market – Market Landscape
4.1 General view
4.2 PEST analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe- PEST Analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 Middle East and Africa – PEST Analysis
4.2.5 South and Central America – PEST Analysis
4.2.6 Expert opinion

5. Insulin market- Key market dynamics
5.1 Market players
5.1.1 Increase in the incidence of diabetes
5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Key Players
5.2 Market Limits
5.2.1 Risks associated with insulin delivery devices
5.3 Market opportunities
5.3.1 Low competition from biosimilars
5.4 Future trends
5.4.1 Diabetic pancreas regeneration, with advanced transplants
5.5 Impact analysis

6. Insulin market- Global analysis
6.1 Global Insulin Market Revenue Forecast and Analysis
6.1.1 Global Insulin Market by Geography – Forecast and Analysis
6.1.2 Global Insulin Market – Market Potential Analysis, by Region
6.2 Company analysis
6.2.1 Market positioning of the main actors
6.2.2 Comparative Company Analysis
6.2.3 Growth strategy analysis
6.2.4 Performance of key players
6.2.4.1 Novo Nordisk A/S
6.2.4.2 Sanofi
6.2.4.3 Eli Lily and company
6.3 Customization section
6.3.1 Analysis of market shares by company
6.3.2 Injectable LPG market share

7. Insulin Market Analysis – By Type
7.1 General view
7.2 Insulin Market Revenue Share by Type (2021 & 2028)
7.3 Long-acting insulin
7.3.1 General view
7.3.2 Long-Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.3.2.1 Levemir
7.3.2.1.1 General view
7.3.2.1.2 Levemir: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.3.2.2 Lantus
7.3.2.2.1 General view
7.3.2.2.2 Lantus: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.3.2.3 Basaglar
7.3.2.3.1 General view
7.3.2.3.2 Basaglar: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.3.2.4 Tresiva
7.3.2.4.1 General view
7.3.2.4.2 Tresiba: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.4 Fast-acting insulins
7.4.1 General view
7.4.2 Rapid-Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.4.2.1 Novolog
7.4.2.1.1 General view
7.4.2.1.2 Novolog: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.4.2.2 Descent
7.4.2.2.1 General view
7.4.2.2.2 Humalog: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.4.2.3 Admelog
7.4.2.3.1 General view
7.4.2.3.2 Admelog: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.4.2.4 Others
7.4.2.4.1 General view
7.4.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.5 Short-acting insulins and traditional human insulins
7.5.1 General view
7.5.2 Short-Acting Insulins and Traditional Human Insulin: Insulin Market – Revenue and Forecast to 2028 ($Million)
7.5.2.1 Novolin R
7.5.2.1.1 General view
7.5.2.1.2 Novolin R: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.5.2.2 Humulin R
7.5.2.2.1 General view
7.5.2.2.2 Humulin R: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.5.2.3 Human
7.5.2.3.1 General view
7.5.2.3.2 Insuman: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.5.2.4 Others
7.5.2.4.1 General view
7.5.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.6 Concentrated insulin and combined insulin
7.6.1 General view
7.6.2 Insulin Concentrates and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 ($Million)
7.6.2.1 NovoMix
7.6.2.1.1 General view
7.6.2.1.2 NovoMix: Insulin Market – Revenue and Forecast to 2028 (USD Million)
7.6.2.2 Ryzodeg
7.6.2.2.1 General view
7.6.2.2.2 Ryzodeg: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.6.2.3 Xultophy
7.6.2.3.1 General view
7.6.2.3.2 Xultophy: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.6.2.4 Soliqua/Suliqua
7.6.2.4.1 General view
7.6.2.4.2 Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 ($ Million)
7.7 Insulin biosimilars
7.7.1 General view
7.7.2 Insulin Biosimilars: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.7.2.1 Insulin Glargine
7.7.2.1.1 General view
7.7.2.1.2 Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 ($Million)
7.7.2.2 Human insulin
7.7.2.2.1 General view
7.7.2.2.2 Human Insulin: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.8 Glucagon-like peptide-1 (GLP-1)
7.8.1 General view
7.8.2 Glucagon-Like Peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.9 Pens and needles
7.9.1 General view
7.9.2 Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (Million USD)
7.10 Others
7.10.1 General view
7.10.2 Others: Insulin Market – Revenue and Forecast to 2028 (Million USD)

8. Global Insulin Market – Geographical Analysis

9. Impact of the COVID-19 pandemic on the global insulin market
9.1 North America: Assessment of the impact of the COVID-19 pandemic
9.2 Europe: Assessment of the impact of the COVID-19 pandemic
9.3 Asia Pacific: Assessment of the impact of the COVID-19 pandemic
9.4 The Middle East and Africa: Assessment of the impact of the COVID-19 pandemic
9.5 South and Central America: Assessment of the impact of the COVID-19 pandemic

10. Insulin market-industry landscape
10.1 Overview
10.2 Insulin Market Growth Strategies (%)
10.3 Organic developments
10.3.1 General view
10.4 Inorganic developments
10.4.1 General view

11. Company profile
11.1 Eli Lilly and Company
11.1.1 Main events
11.1.2 Description of the Business
11.1.3 Products and services
11.1.4 Financial overview
11.1.5 SWOT Analysis
11.1.6 Key developments
11.2 Novo Nordisk A/S
11.2.1 Main events
11.2.2 Description of the Business
11.2.3 Products and services
11.2.4 Financial overview
11.2.5 SWOT Analysis
11.2.6 Key developments
11.3 Biocon
11.3.1 Main events
11.3.2 Description of the Business
11.3.3 Products and services
11.3.4 Financial overview
11.3.5 SWOT Analysis
11.3.6 Key developments
11.4 WOCKHARDT
11.4.1 Main events
11.4.2 Description of the Business
11.4.3 Products and services
11.4.4 Financial overview
11.4.5 SWOT Analysis
11.4.6 Key developments
11.5 Adocia
11.5.1 Main events
11.5.2 Description of the Business
11.5.3 Products and services
11.5.4 Financial overview
11.5.5 SWOT Analysis
11.5.6 Key developments
11.6 GlaxoSmithKline plc.
11.6.1 Main events
11.6.2 Description of the Business
11.6.3 Products and services
11.6.4 Financial overview
11.6.5 SWOT Analysis
11.6.6 Key developments
11.7 Sanofi
11.7.1 Main events
11.7.2 Description of Business
11.7.3 Products and services
11.7.4 Financial overview
11.7.5 SWOT Analysis
11.7.6 Key developments
11.8 Pfizer Inc.
11.8.1 Main events
11.8.2 Description of Business
11.8.3 Products and services
11.8.4 Financial overview
11.8.5 SWOT Analysis
11.8.6 Key developments
11.9 Merck & Co., Inc.
11.9.1 Main events
11.9.2 Description of Business
11.9.3 Products and services
11.9.4 Financial overview
11.9.5 SWOT Analysis
11.9.6 Key developments
11:10 Tonghua Dongbao Pharmaceutical Co., Ltd.
11.10.1 Main events
11.10.2 Description of Business
11.10.3 Products and services
11.10.4 Financial overview
11.10.5 SWOT Analysis
11.10.6 Key developments
11.11 BIGFOOT BIOMEDICAL, INC.
11.11.1 Main events
11.11.2 Description of Business
11.11.3 Products and services
11.11.4 Financial overview
11.11.5 SWOT Analysis
11.11.6 Key developments

12. Appendix

For more information on this report, visit https://www.researchandmarkets.com/r/kqtu93

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Leave a Comment